Lyra Therapeutics

Lyra Therapeutics

Biotechnology Research

Watertown, Massachusetts 8,023 followers

Clinical-stage biotechnology company developing innovative therapies for the localized treatment of CRS

About us

Lyra Therapeutics is a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities. Building on expertise in materials science, drug development and formulation, Lyra has developed proprietary technology that is designed to deliver medicines directly precisely and consistently to the affected tissue for sustained periods with a single administration. Our product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, in-office procedure and intended to deliver up to six months of continuous mometasone furoate drug therapy to the sinonasal passages for the treatment of CRS.

Website
http://www.lyratx.com
Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
Watertown, Massachusetts
Type
Public Company
Founded
2018
Specialties
Pharmaceuticals and Biotechnology

Locations

Employees at Lyra Therapeutics

Updates

Similar pages

Browse jobs

Funding

Lyra Therapeutics 10 total rounds

Last Round

Post IPO equity

US$ 50.0M

See more info on crunchbase